Gainesville, FL, United States of America

Mark A Atkinson

USPTO Granted Patents = 11 (Patent Applications = 7)

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 37(Granted Patents)

Location History:

Gainseville, FL (US) (1997)
Gainesville, FL (US) (1998 - 2023)

Company Filing History:

11 out of 2,928

University of Florida Research Foundation Inc

Arizona State University

patents

where one patent can have more than one assignee

Years Active: 1997-2023

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11567088 - Methods for diagnosis of type 1 diabetes (2023-01-31),

2. 10022440 - Materials and methods for modulating immune responses (2018-07-17),

3. 9700609 - Compositions for treatment and/or prevention of autoimmune disorders (2017-07-11),

4. 9474773 - [object Object] (2016-10-25),

5. 8758761 - Combination therapies for treating type 1 diabetes (2014-06-24),

6. 8594949 - Biomarkers for differentiating between type 1 and type 2 diabetes (2013-11-26),

7. 7648825 - Biomarkers for differentiating between type 1 and type 2 diabetes (2010-01-19),

8. 6300089 - Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus (2001-10-09),

9. 6001360 - Method and compositions for early detection and treatment of insulin (1999-12-14),

10. 5762937 - Methods and compositions for the early detection and treatment of (1998-06-09),

11. 5645998 - Methods and compositions for the early detection and treatment of (1997-07-08),

Title: The Innovations of Mark A. Atkinson

Introduction

Mark A. Atkinson is a prominent inventor based in Gainesville, Florida. He has made significant contributions to the field of medical research, particularly in the diagnosis and treatment of type 1 diabetes. With a total of 11 patents to his name, Atkinson's work has the potential to impact the lives of many individuals suffering from autoimmune diseases.

Latest Patents

Atkinson's latest patents include groundbreaking methods for the diagnosis of type 1 diabetes. His research identifies seventeen antigens as potential biomarkers for early detection and risk prediction of type 1 diabetes. These antigens include MLH1, MTIF3, PPIL2, NUP50, TOX4, FIGN, C9orf142, ZNF280D, HES1, QRFPR, CTRC, SNX6, SYTL4, ELA2A, IGRP, PAX6, and HMGN3. Additionally, he has developed materials and methods for modulating immune responses. This invention provides an initial artificial lymph-node homing environment, which can lead to the resolution of activated immune responses. It has applications in preventing and treating pathogenic infections, cancer, allergenic reactions, and unwanted immune or autoimmune responses.

Career Highlights

Throughout his career, Atkinson has worked with notable organizations such as the University of Florida Research Foundation and Genzyme Corporation. His work in these institutions has allowed him to advance his research and collaborate with other experts in the field.

Collaborations

Atkinson has collaborated with esteemed colleagues, including Noel K. Maclaren and Clive Henry Wasserfall. These partnerships have contributed to the success of his research and the development of innovative solutions in the medical field.

Conclusion

Mark A. Atkinson's contributions to medical research and his innovative patents highlight his dedication to improving the diagnosis and treatment of type 1 diabetes. His work continues to pave the way for advancements in healthcare and offers hope for many individuals affected by autoimmune diseases.

This text is generated by artificial intelligence and may not be accurate.